-
Je něco špatně v tomto záznamu ?
Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study
A. Sharma, JE. Galimard, A. Pryce, SV. Bhoopalan, A. Dalissier, JH. Dalle, F. Locatelli, C. Jubert, O. Mirci-Danicar, V. Kitra-Roussou, Y. Bertrand, F. Fagioli, F. Rialland, A. Biffi, RF. Wynn, G. Michel, FP. Tambaro, A. Al-Ahmari, A. Tbakhi, CL....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
P30CA021765
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
NA
American Lebanese Syrian Associated Charities (ALSAC)
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- akutní myeloidní leukemie * genetika terapie diagnóza MeSH
- chromozomální aberace MeSH
- chromozomální delece MeSH
- dítě MeSH
- homologní transplantace MeSH
- lidé MeSH
- lidské chromozomy, pár 7 MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * metody MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Poor-risk (PR) cytogenetic/molecular abnormalities generally direct pediatric patients with acute myeloid leukemia (AML) to allogeneic hematopoietic stem cell transplant (HSCT). We assessed the predictive value of cytogenetic risk classification at diagnosis with respect to post-HSCT outcomes in pediatric patients. Patients younger than 18 years at the time of their first allogeneic HSCT for AML in CR1 between 2005 and 2022 who were reported to the European Society for Blood and Marrow Transplantation registry were subgrouped into four categories. Of the 845 pediatric patients included in this study, 36% had an 11q23 abnormality, 24% had monosomy 7/del7q or monosomy 5/del5q, 24% had a complex or monosomal karyotype, and 16% had other PR cytogenetic abnormalities. In a multivariable model, 11q23 (hazard ratio [HR] = 0.66, P = 0.03) and other PR cytogenetic abnormalities (HR = 0.55, P = 0.02) were associated with significantly better overall survival when compared with monosomy 7/del7q or monosomy 5/del5q. Patients with other PR cytogenetic abnormalities had a lower risk of disease relapse after HSCT (HR = 0.49, P = 0.01) and, hence, better leukemia-free survival (HR = 0.55, P = 0.01). Therefore, we conclude that PR cytogenetic abnormalities at diagnosis predict overall survival after HSCT for AML in pediatric patients.
Anthony Nolan Research Institute Imperial College Healthcare NHS Trust London UK
Bone Marrow Transplant Unit 2 Children's Clinic University Children's Hospital Bratislava Slovakia
Bone Marrow Transplant Unit St Sophia Children's Hospital Oncology Centre Athens Greece
CHU Bordeaux Groupe Hospitalier Pellegrin Enfants Bordeaux France
Clinical Research Division Fred Hutchinson Cancer Center Seattle WA USA
Département Hématologie Oncologie Pédiatrique Hôpital de la Timone Marseille France
Department of Paediatric Haematology and Oncology University Hospital Motol Prague Czech Republic
Department of Paediatric Oncology Royal Marsden Hospital London UK
Department of Paediatrics King Faisal Specialist Hospital and Research Centre Riyadh Saudi Arabia
Department of Pediatrics Niño Jesus Children's Hospital Madrid Spain
Dipartimento di Ematologia Pediatrica Azienda Ospedaliera di Rilievo Nazionale Naples Italy
EBMT Paris Study Unit Hôpital Saint Antoine Paris France
EBMT Statistical Unit Hôpital Saint Antoine Paris France
Hôpital Armand Trousseau APHP Sorbonne Université Paris France
HSCT Unit Department of Hematology and Oncology IRCCS Institute G Gaslini Genoa Italy
King Hussein Cancer Center Amman Jordan
Oncopediatrics department Nantes University Hospital Nantes France
Paediatric Bone Marrow Transplant Service Bristol Royal Hospital for Children Bristol UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014492
- 003
- CZ-PrNML
- 005
- 20240905133328.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-024-02197-3 $2 doi
- 035 __
- $a (PubMed)38225386
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Sharma, Akshay $u Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA. akshay.sharma@stjude.org $1 https://orcid.org/0000000332812081
- 245 10
- $a Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study / $c A. Sharma, JE. Galimard, A. Pryce, SV. Bhoopalan, A. Dalissier, JH. Dalle, F. Locatelli, C. Jubert, O. Mirci-Danicar, V. Kitra-Roussou, Y. Bertrand, F. Fagioli, F. Rialland, A. Biffi, RF. Wynn, G. Michel, FP. Tambaro, A. Al-Ahmari, A. Tbakhi, CL. Furness, MA. Diaz, P. Sedlacek, I. Bodova, M. Faraci, K. Rao, K. Kleinschmidt, A. Petit, B. Gibson, NS. Bhatt, K. Kalwak, S. Corbacioglu
- 520 9_
- $a Poor-risk (PR) cytogenetic/molecular abnormalities generally direct pediatric patients with acute myeloid leukemia (AML) to allogeneic hematopoietic stem cell transplant (HSCT). We assessed the predictive value of cytogenetic risk classification at diagnosis with respect to post-HSCT outcomes in pediatric patients. Patients younger than 18 years at the time of their first allogeneic HSCT for AML in CR1 between 2005 and 2022 who were reported to the European Society for Blood and Marrow Transplantation registry were subgrouped into four categories. Of the 845 pediatric patients included in this study, 36% had an 11q23 abnormality, 24% had monosomy 7/del7q or monosomy 5/del5q, 24% had a complex or monosomal karyotype, and 16% had other PR cytogenetic abnormalities. In a multivariable model, 11q23 (hazard ratio [HR] = 0.66, P = 0.03) and other PR cytogenetic abnormalities (HR = 0.55, P = 0.02) were associated with significantly better overall survival when compared with monosomy 7/del7q or monosomy 5/del5q. Patients with other PR cytogenetic abnormalities had a lower risk of disease relapse after HSCT (HR = 0.49, P = 0.01) and, hence, better leukemia-free survival (HR = 0.55, P = 0.01). Therefore, we conclude that PR cytogenetic abnormalities at diagnosis predict overall survival after HSCT for AML in pediatric patients.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a homologní transplantace $7 D014184
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a chromozomální delece $7 D002872
- 650 _2
- $a chromozomální aberace $7 D002869
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 12
- $a akutní myeloidní leukemie $x genetika $x terapie $x diagnóza $7 D015470
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a lidské chromozomy, pár 7 $7 D002897
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Galimard, Jacques-Emmanuel $u EBMT Statistical Unit, Hôpital Saint-Antoine, Paris, France $1 https://orcid.org/0000000191024427
- 700 1_
- $a Pryce, Angharad $u Anthony Nolan Research Institute, Imperial College Healthcare NHS Trust, London, UK
- 700 1_
- $a Bhoopalan, Senthil Velan $u Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA $1 https://orcid.org/0000000214026549
- 700 1_
- $a Dalissier, Arnaud $u EBMT Paris Study Unit, Hôpital Saint-Antoine, Paris, France
- 700 1_
- $a Dalle, Jean-Hugues $u Pediatric Hematology and Immunology Department, Hôpital Robert-Debré, GHU APHP Nord Université Paris Cité, Paris, France
- 700 1_
- $a Locatelli, Franco $u Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy $1 https://orcid.org/0000000279763654
- 700 1_
- $a Jubert, Charlotte $u CHU Bordeaux Groupe Hospitalier Pellegrin-Enfants, Bordeaux, France
- 700 1_
- $a Mirci-Danicar, Oana $u Paediatric Bone Marrow Transplant Service, Bristol Royal Hospital for Children, Bristol, UK
- 700 1_
- $a Kitra-Roussou, Vassiliki $u Bone Marrow Transplant Unit, St. Sophia Children's Hospital Oncology Centre, Athens, Greece
- 700 1_
- $a Bertrand, Yves $u Unité de coordination interne et externe, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France
- 700 1_
- $a Fagioli, Franca $u Centro Trapianti Cellule Staminali, Onco-Ematologia Pediatrica, Ospedale Infantile Regina Margherita, Turin, Italy $1 https://orcid.org/000000029257900X
- 700 1_
- $a Rialland, Fanny $u Oncopediatrics department, Nantes University Hospital, Nantes, France $1 https://orcid.org/0000000231366270
- 700 1_
- $a Biffi, Alessandra $u Pediatric Hematology, Oncology and Stem Cell Transplant Division, Padova University and Hospital, Padua, Italy
- 700 1_
- $a Wynn, Robert F $u Blood and Marrow Transplant Unit, Department of Paediatric Haematology, Royal Manchester Children's Hospital, Manchester, UK $1 https://orcid.org/0000000260468428
- 700 1_
- $a Michel, Gérard $u Département Hématologie Oncologie Pédiatrique, Hôpital de la Timone, Marseille, France $1 https://orcid.org/0000000200185709
- 700 1_
- $a Tambaro, Francesco Paolo $u Dipartimento di Ematologia Pediatrica, Azienda Ospedaliera di Rilievo Nazionale, Naples, Italy $1 https://orcid.org/0000000291453691
- 700 1_
- $a Al-Ahmari, Ali $u Department of Paediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia $1 https://orcid.org/0000000287325611
- 700 1_
- $a Tbakhi, Abdelghani $u King Hussein Cancer Center, Amman, Jordan
- 700 1_
- $a Furness, Caroline L $u Department of Paediatric Oncology, Royal Marsden Hospital, London, UK
- 700 1_
- $a Diaz, Miguel Angel $u Department of Pediatrics, Niño Jesus Children's Hospital, Madrid, Spain
- 700 1_
- $a Sedlacek, Petr $u Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Bodova, Ivana $u Bone Marrow Transplant Unit, II Children's Clinic, University Children's Hospital, Bratislava, Slovakia
- 700 1_
- $a Faraci, Maura $u HSCT Unit, Department of Hematology and Oncology, IRCCS Institute G. Gaslini, Genoa, Italy $1 https://orcid.org/000000015715501X
- 700 1_
- $a Rao, Kanchan $u Department of Bone Marrow Transplantation, Great Ormond Street Hospital NHS Foundation Trust, London, UK
- 700 1_
- $a Kleinschmidt, Katharina $u Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany $1 https://orcid.org/0000000214477286
- 700 1_
- $a Petit, Arnaud $u Hôpital Armand Trousseau, APHP, Sorbonne Université, Paris, France $1 https://orcid.org/0000000183631622
- 700 1_
- $a Gibson, Brenda $u The Royal Hospital for Children, Glasgow, UK
- 700 1_
- $a Bhatt, Neel S $u Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA $1 https://orcid.org/0000000320331125
- 700 1_
- $a Kalwak, Krzysztof $u Clinical Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wrocław Medical University, Wrocław, Poland $1 https://orcid.org/0000000311745799
- 700 1_
- $a Corbacioglu, Selim $u Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany $1 https://orcid.org/0000000310708486
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 59, č. 4 (2024), s. 451-458
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38225386 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133322 $b ABA008
- 999 __
- $a ok $b bmc $g 2143944 $s 1226358
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 59 $c 4 $d 451-458 $e 20240115 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- GRA __
- $a P30CA021765 $p U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- GRA __
- $a NA $p American Lebanese Syrian Associated Charities (ALSAC)
- LZP __
- $a Pubmed-20240725
